File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Relative efficacy and tolerability of lacidipine and amlodipine in patients with mild-to-moderate hypertension: A randomized double-blind study

TitleRelative efficacy and tolerability of lacidipine and amlodipine in patients with mild-to-moderate hypertension: A randomized double-blind study
Authors
KeywordsChemicals And Cas Registry Numbers
Issue Date1996
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.cardiovascularpharm.com/
Citation
Journal Of Cardiovascular Pharmacology, 1996, v. 28 n. 2, p. 328-331 How to Cite?
AbstractCalcium channel blockers are increasingly used in the treatment of hypertension. Newer calcium channel blockers of the dihydropyridine group have longer elimination half-lives (t( 1/4 )) that permit once-daily dosage and are generally better tolerated than their parent compound. In this study, the efficacy and safety of lacidipine and amlodipine were compared in 65 patients with mild-to-moderate hypertension attending the hypertension outpatient clinic of a teaching hospital in a randomized double-blind cross-over trial with dose titration. Lacidipine and amlodipine both significantly reduced systolic blood pressure (SBP: by 19.2 ± 13.5 and 22.3 ± 15.3 mm Hg, respectively) and diastolic BP (DBP; 13.3 ± 4.2 and 12.3 ± 5.3 mm Hg, respectively) 24 h postdose. There were no significant differences in their antihypertensive effects. The incidence of adverse events (AE) was 3% for lacidipine and 8% for amlodipine. The incidence of withdrawal from the study due to side effects was 0% for lacidipine and 3% for amlodipine. These results suggest that lacidipine is well-tolerated, and is as effective us amlodipine as a once-daily antihypertensive agent.
Persistent Identifierhttp://hdl.handle.net/10722/91581
ISSN
2015 Impact Factor: 2.462
2015 SCImago Journal Rankings: 0.962
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLau, CPen_HK
dc.contributor.authorCheung, BMYen_HK
dc.date.accessioned2010-09-17T10:21:42Z-
dc.date.available2010-09-17T10:21:42Z-
dc.date.issued1996en_HK
dc.identifier.citationJournal Of Cardiovascular Pharmacology, 1996, v. 28 n. 2, p. 328-331en_HK
dc.identifier.issn0160-2446en_HK
dc.identifier.urihttp://hdl.handle.net/10722/91581-
dc.description.abstractCalcium channel blockers are increasingly used in the treatment of hypertension. Newer calcium channel blockers of the dihydropyridine group have longer elimination half-lives (t( 1/4 )) that permit once-daily dosage and are generally better tolerated than their parent compound. In this study, the efficacy and safety of lacidipine and amlodipine were compared in 65 patients with mild-to-moderate hypertension attending the hypertension outpatient clinic of a teaching hospital in a randomized double-blind cross-over trial with dose titration. Lacidipine and amlodipine both significantly reduced systolic blood pressure (SBP: by 19.2 ± 13.5 and 22.3 ± 15.3 mm Hg, respectively) and diastolic BP (DBP; 13.3 ± 4.2 and 12.3 ± 5.3 mm Hg, respectively) 24 h postdose. There were no significant differences in their antihypertensive effects. The incidence of adverse events (AE) was 3% for lacidipine and 8% for amlodipine. The incidence of withdrawal from the study due to side effects was 0% for lacidipine and 3% for amlodipine. These results suggest that lacidipine is well-tolerated, and is as effective us amlodipine as a once-daily antihypertensive agent.en_HK
dc.languageengen_HK
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.cardiovascularpharm.com/en_HK
dc.relation.ispartofJournal of Cardiovascular Pharmacologyen_HK
dc.subjectChemicals And Cas Registry Numbersen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAmlodipine - adverse effects - therapeutic useen_HK
dc.subject.meshAntihypertensive Agents - adverse effects - therapeutic useen_HK
dc.subject.meshBlood Pressure - drug effectsen_HK
dc.subject.meshDihydropyridines - adverse effects - therapeutic useen_HK
dc.subject.meshDouble-Blind Methoden_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHalf-Lifeen_HK
dc.subject.meshHumansen_HK
dc.subject.meshHypertension - drug therapy - physiopathologyen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshPulse - drug effectsen_HK
dc.titleRelative efficacy and tolerability of lacidipine and amlodipine in patients with mild-to-moderate hypertension: A randomized double-blind studyen_HK
dc.typeArticleen_HK
dc.identifier.emailCheung, BMY:mycheung@hku.hken_HK
dc.identifier.authorityCheung, BMY=rp01321en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1097/00005344-199608000-00021en_HK
dc.identifier.pmid8856491-
dc.identifier.scopuseid_2-s2.0-0029744431en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0029744431&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume28en_HK
dc.identifier.issue2en_HK
dc.identifier.spage328en_HK
dc.identifier.epage331en_HK
dc.identifier.isiWOS:A1996VB45100021-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLau, CP=7401968501en_HK
dc.identifier.scopusauthoridCheung, BMY=7103294806en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats